A 12-month clinical trial will test whether the antidepressant citalopram can improve the debilitating negative symptoms of schizophrenia—such as emotional flatness, lack of drive, and social withdrawal—in 360 patients across seven UK centres. Negative symptoms are a major reason people with schizophrenia struggle to hold jobs, maintain relationships, or live independently. Unlike hallucinations or delusions, these symptoms often persist even when antipsychotic medication controls the positive ones. Yet there is almost no solid evidence for any treatment that specifically targets them. This trial directly addresses that gap. If citalopram proves effective, it would give clinicians a cheap, widely available, and already-licensed drug to treat a dimension of schizophrenia that currently has no reliable pharmacological option. That could improve patients’ quality of life and social functioning over the long term, reducing the personal and economic burden of the illness. The trial also includes a health-economic analysis, so funders will know whether any benefit is worth the cost. If the drug fails, the trial will still provide high-quality data on what does not work, sparing future patients from ineffective treatments.
View original technical description
The negative symptoms of schizophrenia represent an important dimension of psychopathology, and reflect the absence or diminution of normal behaviours and functions. They include deficiencies in emotional responsiveness, drive, and emotional and social engagement. Persistent negative symptoms are held to account for much of the long-term morbidity and poor functional outcome in patients with established schizophrenia, but if they prove resistant to antipsychotic medication there is a very limited evidence base regarding specific treatments. The aim of this double-blind, placebo-controlled trial is to establish the clinical and cost effectiveness of an SSRI antidepressant, citalopram, in the management of negative symptoms of schizophrenia over a year. The study sample will be adults with an OPCRIT diagnosis of schizophrenia, clinically stable for 3 months with a consistent antipsychotic regimen, and characterised by persistent negative symptoms to a criterion level of severity. The study will be submitted for adoption by the Mental Health Research Network (MHRN) and conducted at seven centres: Bristol, North London, West London, South London, Manchester, Oxford, and Southampton. Consenting participants will be randomly assigned to be additional treatment with either citalopram (20mg/day for the first 4 weeks, followed by 40mg per day for the remainder of the study period) or identical placebo. 360 patients will be recruited over an 18-month period, and each participant followed-up for 12 months. All outcomes scales will be administered at baseline and subsequently 3, 9 and 12 months. Primary outcomes will be quality-of-life at 3 and 12 months, and negative symptoms. Secondary outcomes will include the EuroQol EQ-5D for health economics. Symptoms will be comprehensively assessed, and other measures will assess social function, medication side effects, treatment adherence and cognition. The statistical analysis of the data will be guided by the CONSORT statement on reporting clinical trials.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know